Hologic completes acquisition of Biotheranostics | 合法醫療器材資訊網

2021年2月26日—26,2021–HologichascompleteditsacquisitionofBiotheranosticsforabout$230million.BiotheranosticsdevelopsandmarketsBreastCancer ...

Feb. 26, 2021–Hologic[2] has completed its acquisition of Biotheranostics for about $230 million. Biotheranostics develops and markets Breast Cancer Index and CancerType ID, two molecular diagnostic tests for breast and metastatic cancers­­.

Breast Cancer Index is recommended by the NCCN for prediction of which early-stage hormone receptor positive breast cancer patients are likely to benefit from extended endocrine therapy. The test is also included in guidelines from the American Society for Clinical Oncology.

The CancerType ID test provides a molecular diagnosis for patients with uncertain or unknown cancers. The test compares genomic tumor information with a reference database to find the closest match.